# Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T

> **NCT06224049** · EARLY_PHASE1 · RECRUITING · sponsor: **BGI, China** · enrollment: 6 (estimated)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **BIOLOGICAL:** hNeo-T
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06224049
- **Lead sponsor:** BGI, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224049, "Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06224049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*